Two Secondary Primary Malignancies after Bortezomib Therapy for Multiple Myeloma: A Single-center Experience

Two Secondary Primary Malignancies after Bortezomib Therapy for Multiple Myeloma: A Single-center Experience

Bibliographic Details
Main Authors:	Tian-Jiao Guo, Xiao-Jun Huang, Lei Wen, Jin Lu
Format:	Article
Language:	English
Published:	Wolters Kluwer 2017-01-01
Series:	Chinese Medical Journal
Subjects:	Bortezomib; Multiple Myeloma; Secondary Primary Malignancies
Online Access:	http://www.cmj.org/article.asp?issn=0366-6999;year=2017;volume=130;issue=2;spage=239;epage=241;aulast=Guo

Similar Items

Effectiveness of bortezomib and bortezomib-containing programs FOR the treatment of recurrent and resistant multiple myeloma
by: T A Mitina, et al.
Published: (2010-07-01)

Bortezomib a safety treatment for patients with Multiple Myeloma and Cystic Fibrosis
by: Fabiana Gentilini, et al.
Published: (2012-01-01)

Bortezomib a safety treatment for patients with Multiple Myeloma and Cystic Fibrosis
by: Fabiana Gentilini, et al.
Published: (2012-05-01)

Reduced weekly subcutaneous doses of bortezomib in combination with cyclophosphamide and dexamethasone for newly diagnosed multiple myeloma
by: Farzaneh Ashrafi, et al.
Published: (2020-01-01)

Update on the optimal use of bortezomib in the treatment of multiple myeloma
by: Mohan M, et al.
Published: (2017-03-01)

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
by: Mir Sadaqat Hassan Zafar, et al.
Published: (2018-01-01)

Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide
by: T.B.M. Castro, et al.
Published: (2016-01-01)

Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
by: N. O’Connor-Byrne, et al.
Published: (2019-02-01)

Management of Multiple Myeloma and Usage of Bortezomib: Perspective from India and Ukraine
by: India and Ukraine Haemato-oncology Group, et al.
Published: (2016-11-01)

Chalazia development in multiple myeloma: a new complication associated with bortezomib therapy
by: Charles Yun, et al.
Published: (2015-06-01)

Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma
by: Zhihong Zheng, et al.
Published: (2018-02-01)

Cost-effectiveness of bortezomib for multiple myeloma: a systematic review
by: Chen W, et al.
Published: (2016-05-01)

Bortezomib resistance in multiple myeloma is associated with increased serine synthesis
by: Esther A. Zaal, et al.
Published: (2017-08-01)

Effect of Bortezomib on immune function, inflammatory response and renal function in patients with multiple myeloma
by: Rong-Fang Tang, et al.
Published: (2019-04-01)

Multiple myelomda kromozomal aberasyonlar: klinik sonuçlar ve bortezomib’ e yanıt
by: Arbil AÇIKALIN, et al.
Published: (2019-06-01)

VAD Chemotherapy Versus Bortezomib Containing Regimens As Remission Induction For ASCT in Multiple Myeloma: A Single Center Experience
by: Aysun Senturk Yikilmaz, et al.
Published: (2020-10-01)

Treatment and prognostic factors for survival in newly diagnosed multiple myeloma patients with bortezomib and dexamethasone regimen: a single Chinese center retrospective study
by: Chen R, et al.
Published: (2017-08-01)

HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma
by: Sang Wu Lee, et al.
Published: (2021-01-01)

Herpes zoster in multiple myeloma patients during bortezomib treatment
by: I. N. Nazarova, et al.
Published: (2014-07-01)

Herpes zoster in multiple myeloma patients during bortezomib treatment
by: I. N. Nazarova, et al.
Published: (2014-07-01)

Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
by: Se Ryeon Lee, et al.
Published: (2019-11-01)

Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma
by: Taleb Azarm, et al.
Published: (2012-01-01)

Efficacy and safety of bortezomib with dexamethasone regimen in elderly newly diagnosed multiple myeloma patients with co-morbidities
by: Lee, Saem
Published: (2016)

Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma
by: Shang-Yi Huang, et al.
Published: (2019-01-01)

The Effect of Thiamine in Reducing the Symptoms of Bortezomib-Induced Peripheral Neuropathy in Patients with Multiple Myeloma
by: Valiollah Mehrzad, et al.
Published: (2020-02-01)

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01)

Attenuation of STAT3 Signaling Cascade by Daidzin Can Enhance the Apoptotic Potential of Bortezomib against Multiple Myeloma
by: Min Hee Yang, et al.
Published: (2019-12-01)

Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells
by: Tibullo eDaniele, et al.
Published: (2015-10-01)

Subcutaneous bortezomib might be standard of care for patients with multiple myeloma: a systematic review and meta-analysis
by: Ye Z, et al.
Published: (2019-05-01)

Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma
by: K. A. Belousov, et al.
Published: (2019-04-01)

Effect of bortezomib on the efficiency of hematopoietic stem cell mobilization in patients with multiple myeloma
by: O S Pokrovskaia, et al.
Published: (2012-07-01)

Dorsal Column Degeneration after Bortezomib Therapy in a Patient with Multiple Myeloma
by: Tatsuro Joh, et al.
Published: (2009-10-01)

Analysis of the efficacy and safety of bortezomib for treating newly diagnosed multiple myeloma through different administration methods
by: Zhang HM, et al.
Published: (2019-09-01)

Bortezomib Treatment Modulates Autophagy in Multiple Myeloma
by: Giuseppe Di Lernia, et al.
Published: (2020-02-01)

Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen
by: Hee-Jeong Cho, et al.
Published: (2018-06-01)

Additive Benefits of Radium-223 Dichloride and Bortezomib Combination in a Systemic Multiple Myeloma Mouse Model
by: Mari I. Suominen, et al.
Published: (2021-05-01)

The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients
by: Paweł Robak, et al.
Published: (2020-09-01)

Cost-effectiveness of lenalidomide in combination with dexamethasone compared to bortezomib in combination with dexamethasone for the second-line treatment of multiple myeloma in Chile
by: Susana Aceituno, et al.
Published: (2018-06-01)

Fatal Cytomegalovirus Pneumonia and Associated Herpes Virus Infection in a Relapsed/Refractory Multiple Myeloma Patient Treated with Bortezomib plus Dexamethasone
by: Daisuke Taniguchi, et al.
Published: (2009-07-01)

Inhibition of Multiple Myeloma Using 5-Aza-2ʹ-Deoxycytidine and Bortezomib-Loaded Self-Assembling Nanoparticles
by: Che F, et al.
Published: (2020-08-01)